122 hasil untuk "Kohanbash, Gary"
Menampilkan 1–20 · 0,71 detik · RSS
-
Artikel Jurnal Teks lengkap
MicroRNAs and STAT Interplay
MicroRNA (miR) are emerging as important gene expression regulators often involved in a variety of pathogenesis such as cancers and autoimmunity. Signal Transducers and Activators of Transcription (STAT) proteins are the principle signaling proteins for many cytokines and growth factors, thereby…
-
Artikel Jurnal Teks lengkap
MicroRNAs in Immune Regulation - Opportunities for Cancer Immunotherapy
Endogenously produced microRNAs are predicted to regulate the translation of over two-thirds all human gene transcripts. Certain microRNAs regulate expression of genes that are critically involved in both innate and adaptive immune responses. Immune cells represent a highly attractive target for…
-
Artikel Jurnal Teks lengkap
EXTH-85. ASSESSMENT OF ANTI-CD69 ANTIBODY THERAPY ALONE OR IN COMBINATION WITH ANTI-PD-1 IN MURINE GBM
BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive central nervous system malignancy with a dismal prognosis. There is continued interest in trying multiple immunotherapy modalities for this intractable cancer. Cluster of differentiation 69 (CD69), is an early marker of T and NK cell…
-
Artikel Jurnal Teks lengkap
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases
Melanoma brain metastases (BMs) pose a significant clinical challenge. This commentary highlights the emerging understanding of the mechanisms behind immune-checkpoint blockade (ICB) efficacy in melanoma BMs. Specifically, we focus on a recent study by Fife et al, which revealed a non-canonical…
-
Artikel Jurnal Teks lengkap
TMIC-34. Na/H EXCHANGER ISOFORM 1 (NHE1) IN IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN MOUSE SYNGENEIC GLIOMA MODEL
Glioblastoma is the most common and aggressive brain tumor with a median survival of ~15 months. Clinical trials of patients for immunotherapy showed an inferior response, which can in part attribute to an immunosuppressive, acidic tumor microenvironment (TME) composed of glioma-associated…
-
Artikel Jurnal Teks lengkap
ONO-AE3-208 inhibits myeloid derived suppressor cells and glioma growth
-
Artikel Jurnal Teks lengkap
Pre-clinical models for evaluating glioma targeted immunotherapies
Gliomas have an extremely poor prognosis in both adult and pediatric patient populations as these tumors are known to grow aggressively and respond poorly to standard of care treatment. Currently, treatment for gliomas involves surgical resection followed by chemoradiation therapy. However, some…
-
Artikel Jurnal Teks lengkap
Transgene-derived overexpression of miR-17-92 in CD8(+) T-cells confers enhanced cytotoxic activity
MicroRNAs (miRs) play important roles in regulation of a variety of cell functions, including immune responses. We have previously demonstrated that miR-17-92 expression in T-cells enhances Th1 phenotype and provides a long-term protection against glioblastoma when co-expressed as a transgene in…
-
Artikel Jurnal Teks lengkap
TMIC-51. SEX-SPECIFIC T CELL BEHAVIOR DRIVES DIFFERENTIAL IMMUNE RESPONSES IN GLIOBLASTOMA
Glioblastoma (GBM) is the most common primary malignant brain tumor and shows poor outcomes as a median survival is 12-18 months with current standard-of-care of therapy. GBM exhibits sex differences in incidence and overall survival, with males experiencing a higher incidence and a worse prognosis…
-
Artikel Jurnal Teks lengkap
EXTH-42. GLIOMA-DERIVED CD200 PROMOTES TUMOR GROWTH AND SUPPRESSES NK CELL AND CD8 T CELL ANTI-GLIOMA ACTIVITY
Immune-checkpoint inhibitors, such as anti-PD1 and anti-CTLA4, have emerged as promising therapeutic options for several malignancies yet show little efficacy against malignant brain cancers. CD200 is a newly recognized immune-checkpoint which is expressed by a marid of cell types, modulating…
-
Artikel Jurnal Teks lengkap
IDH mutation-induced suppression of type-1 anti-glioma immune response
-
Artikel Jurnal Teks lengkap
TMIC-39. DEVELOPMENT OF CD11b TRACER FOR THE IMMUNE PET IMAGING IN GLIOBLASTOMA MODEL - COULD BE A GAME CHANGER FOR IMMUNOTHERAPY APPROACHES
Glioblastoma is a lethal brain tumor, heavily infiltrated by tumor-associated myeloid cells (TAMCs). As up to 30% of a glioma cellular mass may be attributed to immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). TAMCs impede…
-
Artikel Jurnal Teks lengkap
IMMU-06. Landscape of adaptive immunity of childhood brain cancers
T lymphocytes have a unique ability to recognize a vast array of antigens prompted by an enormous T cell receptor (TCR) repertoire. Characterization of tumor-infiltrating T cells (TILs) is key to understand MHC-restricted anti-tumor immunity and for developing T cell-centered immunotherapies such…
-
Artikel Jurnal Teks lengkap
Glioblastoma vaccines: past, present, and opportunities
Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in adults. As supplements to standard of care (SOC), various immunotherapies improve the therapeutic effect in other cancers. Among them, tumour vaccines can serve as complementary monotherapy or boost the clinical…
-
Artikel Jurnal Teks lengkap
IMMU-16. GUADECITABINE (SGI-110) ENHANCES MHC class I AND TUMOR ANTIGEN EXPRESSION ON MURINE C57BL/6-SYNGENEIC GLIOMA AND DIPG MODELS
Diffuse intrinsic pontine glioma (DIPG) is one of the most lethal pediatric brain tumors, with a median survival time of less than one year. As DIPG tumors are insensitive to chemotherapy and surgically inaccessible, there is an urgent need for the development of novel therapeutic approaches. Our…
-
Artikel Jurnal Teks lengkap
TMIC-19. H(+) EXTRUSION PROTEIN NA/H EXCHANGER IN METABOLIC POLARIZATION OF GLIOMA-ASSOCIATED MICROGLIA/MACROPHAGES AND TUMOR IMMUNITY
Immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) attributes to poor efficacy of chemotherapy and/or immunotherapy. We recently reported that SLC9A1 gene expression (Na/H exchanger 1, NHE1) in GBM tumor correlates with increased macrophage tumor infiltration and worsened patient…
-
Artikel Jurnal Teks lengkap
Protocol to assess the antitumor efficacy of an immunotherapeutic peptide in syngeneic orthotopic glioma mouse models
Understanding the glioblastoma (GBM) immune microenvironment and development of clinical treatment drugs rely on suitable preclinical GBM models. Here, we present a protocol to establish syngeneic orthotopic glioma mouse models. We also describe the steps to intracranially deliver immunotherapeutic…
-
Artikel Jurnal Teks lengkap
Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody
Targeting molecules, such as antibodies and peptides, play a key role in the precise delivery of cytotoxic payloads to tumor sites by binding to specific tumor-associated antigens or other proteins within the tumor microenvironment. This investigation evaluates the potential therapeutic application…
-
Artikel Jurnal Teks lengkap
IMMU-21. DEVELOPMENT OF PET TRACERS FOR NON-INVASIVE IMAGING OF IMMUNOTHERAPY IN DIFFUSE INTRINSIC PONTINE GLIOMA
DIPG is an incurable brain tumor with median overall survival times of less than 10 months, with current treatment. Immunotherapy is an attractive approach for some DIPG patients based on promising clinical and preclinical studies. However, due to surgical inaccessibility, intratumoral…
-
Artikel Jurnal Teks lengkap
CSIG-01. NA-K-CL COTRANSPORTER PROTEIN IN THE PATHOGENESIS OF LOW-GRADE GLIOMAS
Low-grade gliomas (LGGs) present a high incidence of epilepsy, infiltrative growth, resistance to therapy, and high risk of transforming into high-grade gliomas (HGGs). Temozolomide (TMZ) is a conventional chemotherapy drug for adjuvant treatment of patients with high-risk LGGs. Na(+)-K(+)-2Cl(-)…